Intercept Pharmaceuticals develops transformative therapies for patients with rare and serious liver diseases. The company's flagship product, obeticholic acid (OCA), is a first-in-class treatment approved for primary biliary cholangitis (PBC), a rare autoimmune liver disease. With a commitment to advancing care, Intercept aims to expand its research pipeline, exploring innovative treatments for illnesses like severe alcohol-associated hepatitis. The organization emphasizes collaboration, patient-centricity, and inclusivity within its culture, fostering a work environment where employees from diverse backgrounds can thrive and contribute meaningfully. At Intercept, professionals are encouraged to embrace challenges, engage in continuous learning, and take part in the pursuit of improving patient health outcomes.